Compare Fox Corp Class A (FOXA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs TG Therapeutics Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $24.58B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Fox Corp Class A is far larger — about 3.2× TG Therapeutics Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FOXA | TGTX | |
|---|---|---|
Market Cap | $24.58B | $7.64B |
Sector | Media | Health |
52-Week High | $76.11 | $59.06 |
52-Week Low | $48.79 | $26.94 |
Enterprise Value | $27.94B | $7.84B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.05, down 0.58% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate, and revenue growth from $14.0B in 2024 to $16.3B in 2025. Recent news highlights World Cup-driven ad revenue and Tubi streaming growth as key catalysts.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, but risks include declining 2026 net income projections and high RSI levels suggesting overbought conditions. The stock offers value with a P/E of 16.18 and robust cash flow, though investors should monitor sports cost pressures and debt levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
